Too little, too soon: Japan's experiment in regenerative medicine deregulation

Area of Science:

• Biomedical Science
• Regulatory Science
• Health Policy

Background:

• Japan introduced a conditional approval pathway in 2013 for advanced therapies.
• This pathway aimed to expedite access to novel cell and gene therapies.

Purpose of the Study:

• To evaluate the quality of safety and efficacy data for products approved via Japan's conditional pathway.
• To assess the overall success and reliability of this regulatory framework.

Main Methods:

• Analysis of regulatory submission data for cell and gene therapy products.
• Review of safety and efficacy evidence presented for four conditionally approved products.

Main Results:

• Identified significant shortcomings in the submitted safety data.
• Found evidence of inadequate efficacy data supporting product approval.
• Concerns raised regarding the robustness of the approval process.

Conclusions:

• The current conditional approval pathway may not adequately ensure the safety and efficacy of approved cell and gene therapies.
• Further scrutiny of data requirements and post-market surveillance is warranted.